- Company’s investigational drug is being tested for the first time ever on humans in an FDA-approved study
- In phase 1 studies, IGC-AD1 shows potential to safely reduce debilitating symptoms
- IGC is actively building a portfolio of both cannabis-based and manufactured molecules that can address multiple areas of unmet medical needs
In groundbreaking work that establishes its commitment to being a pioneer in the treatment of Alzheimer’s disease, India Globalization Capital (NYSE American: IGC) is developing a cannabis-based investigational drug that is being tested for the first time ever on humans in an FDA-approved study (https://cnw.fm/6qps2). The company is developing its proprietary treatment, IGC-AD1, hoping to provide relief to the 55 million people worldwide struggling with agitation in dementia that results from Alzheimer’s.
IGC is focused on revolutionizing the treatment of Alzheimer’s with its game-changing treatment. In phase 1 studies, IGC-AD1 shows potential to safely reduce the debilitating symptoms that impact millions of Alzheimer’s patients and their caregivers. Featuring a low dose of THC, the treatment is the first natural cannabis-based investigational drug being tested in human FDA trials to treat Alzheimer’s patients; it provides medical benefits without psychoactive effects. “As millions of Alzheimer’s patients continue to suffer from agitation, anxiety, and depression, phase 2 clinical trials bring hope for a treatment,” the company reports.
In addition to IGC-AD1, IGC is actively building a portfolio of both cannabis-based and manufactured molecules that can address multiple areas of unmet medical needs (https://cnw.fm/67wqT). The company’s TGR-63 product is being studied for its potential to decrease Alzheimer’s markers, including plaque buildup, while also decreasing cognitive decline and improving memory. The company also has undisclosed molecules involved in exploratory activities.
With no current FDA-approved drugs to treat in Alzheimer’s patients, the company clearly has found a place where it can establish a foothold. In fact, last year less than 7% of drugs in clinical trials were focused on treating neuropsychiatric symptoms of Alzheimer’s. The time has clearly come for IGC. “What we do is important,” the company states. “With no known cure, our formulations have the potential to change lives.”
IGC develops advanced cannabinoid-based formulations for treating diseases, including but not limited to Alzheimer’s disease, Parkinson’s disease, chronic pain, and even pet seizures. The company sells various brands of CBD-based consumer products, including Holief, which includes gummies and pain relief creams for women experiencing premenstrual syndrome and dysmenorrhea (period cramps), and Sunday Seltzer, which includes a CBD-infused energy beverage. The company operates facilities in the United States under Good Manufacturing Practices.
For more information, visit the company’s website at www.IGCPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to IGC are available in the company’s newsroom at https://ibn.fm/IGC
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.cbdwire.com
Do you have questions or are you interested in working with CNW? Ask Our Editor
CBDWire is part of the InvestorBrandNetwork.